Status:

RECRUITING

GCS Survey: "GHB IN CHEMICAL SUBMISSION: MYTH OR REALITY?"

Lead Sponsor:

Assistance Publique - Hôpitaux de Paris

Collaborating Sponsors:

Mission Interministérielle de Lutte contre les Drogues et les Conduites Addictives - MILDECA

Conditions:

CHEMICAL SUBMISSION

Eligibility:

All Genders

18+ years

Brief Summary

According to the media, GHB is the main substance used for chemical submission. The national survey conducted by the Addictovigilance centre of Paris on drug-facilitated assaults shows that GHB is use...

Detailed Description

The Addictovigilance center of Paris (CEIP-A) has been responsible for the national chemical submission survey under the supervision of the French National Agency for the Safety of Medicines and Healt...

Eligibility Criteria

Inclusion

  • Victims over the age of majority (≥ 18 years) on the day of the alleged events
  • With a medical history leading to the suspicion of chemical submission:
  • Presence of evocative clinical signs (amnesia and/or behavioural disorders and/or neurological disorders and/or other somatic disorders, etc.) AND
  • In the presence of potential criminal acts (suspected or proven assault or attempted assault).
  • French speaking
  • Having been informed of the search

Exclusion

  • \- Victims who were minors (\<18 years) on the day of the alleged events.
  • Victims who usually use GHB/GBL recreationally.
  • Suspecting administration of a harmful substance with no crime or offence committed at the time and no attempted assault
  • Victims of needle spiking
  • Victims with very short hair (\<3 cm), bald or shaven heads
  • Victims who have exceeded the maximum time limit for taking a hair sample (6 months after the event)
  • Do not speak French
  • Oppose to participating in the study
  • Victims presenting a psychotic or cognitive syndrome likely to impair judgement Victims placed under guardianship or legal protection (article L11-22-2 CSP)

Key Trial Info

Start Date :

March 20 2024

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

March 20 2026

Estimated Enrollment :

200 Patients enrolled

Trial Details

Trial ID

NCT06137599

Start Date

March 20 2024

End Date

March 20 2026

Last Update

July 3 2024

Active Locations (3)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (3 locations)

1

Laetitia LASNE

Bondy, France, 93140

2

Elisabeth ALCARAZ

Paris, France, 75004

3

Leila CHAOUACHI

Paris, France, 75010